Many G-protein coupled receptors involved in pain and addiction are pharmacologically and biochemically well characterized, but some orphan receptors like GPR35 and GPR55, with homology to known receptors for drugs of abuse, remain poorly characterized. GPR55 is emerging as an important target in inflammatory pain, neuropathic pain, and bone development while other studies indicate that GPR55 activation is pro-carcinogenic. GPR55 does recognize certain cannabinoid ligands, so it has been suggested to be a third cannabinoid receptor. GPR35 is an important target in pain (spinal antinociception as well as inflammatory pain), heart disease, asthma, metabolic disease, inflammatory bowel disease and cancer. Each of these areas alone is medically important and each would benefit by the use of selective agonists and antagonists to further studies in their respective animal models. However, to date, no low nanomolar potency ligands have been discovered for these receptors nor is there a radioligand developed to characterize binding. The lack of such ligands is a critical barrier to progress in this field. The goal of this proposal is to leverage our recen promising high throughput, high content screening results for GPR55 agonists and GPR35 antagonists using structure based design and cheminformatics tools to develop an SAR for selected scaffolds that leads to the identification of low nanamolar ligands that retain high receptor selectivity.
We aim to discover nanomolar potency GPR55 and GPR35 ligands using a combination of structure-based design, molecular modeling, chemoinformatics, high-throughput screening and site directed mutagenesis.
Many G-protein coupled receptors involved in pain and addiction are pharmacologically and biochemically well characterized, but some orphan receptors like GPR35 and GPR55, with homology to known receptors for drugs of abuse, remain poorly characterized. Both GPR55 and GPR35 are emerging as important targets in inflammatory pain, cancer and metabolic disease, to name a few. However, the lack of potent agonists and antagonists for these receptors are a critical barrier to progress this field. The goa of this proposal is to leverage our recent promising high throughput screening results for GPR55 agonists and GPR35 antagonists to develop such ligands.
|Meza-AviÃ±a, Maria Elena; Lingerfelt, Mary A; Console-Bram, Linda M et al. (2016) Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones. Bioorg Med Chem Lett 26:1827-30|
|Lin-Moshier, Yaping; Keebler, Michael V; Hooper, Robert et al. (2014) The Two-pore channel (TPC) interactome unmasks isoform-specific roles for TPCs in endolysosomal morphology and cell pigmentation. Proc Natl Acad Sci U S A 111:13087-92|
|Lucchesi, Valentina; Hurst, Dow P; Shore, Derek M et al. (2014) CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides. J Med Chem 57:8777-91|
|Rahman, Taufiq; Cai, Xinjiang; Brailoiu, G Cristina et al. (2014) Two-pore channels provide insight into the evolution of voltage-gated Ca2+ and Na+ channels. Sci Signal 7:ra109|
|Console-Bram, Linda; Brailoiu, Eugen; Brailoiu, Gabriela Cristina et al. (2014) Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol 171:3908-17|
|Zhao, Pingwei; Lane, Tom R; Gao, Helen G L et al. (2014) Crucial positively charged residues for ligand activation of the GPR35 receptor. J Biol Chem 289:3625-38|
|Brailoiu, G Cristina; Deliu, Elena; Marcu, Jahan et al. (2014) Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry 53:4990-9|
|Kotsikorou, Evangelia; Sharir, Haleli; Shore, Derek M et al. (2013) Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52:9456-69|
|Marcu, Jahan; Shore, Derek M; Kapur, Ankur et al. (2013) Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther 345:189-97|
|Baillie, Gemma L; Horswill, James G; Anavi-Goffer, Sharon et al. (2013) CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83:322-38|
Showing the most recent 10 out of 21 publications